IS2092B - 8-azabísýkló(3,2,1)okt-2-en og oktanafleiður sem kólínergir bindlar á nikótín ach viðtakanum - Google Patents

8-azabísýkló(3,2,1)okt-2-en og oktanafleiður sem kólínergir bindlar á nikótín ach viðtakanum

Info

Publication number
IS2092B
IS2092B IS5243A IS5243A IS2092B IS 2092 B IS2092 B IS 2092B IS 5243 A IS5243 A IS 5243A IS 5243 A IS5243 A IS 5243A IS 2092 B IS2092 B IS 2092B
Authority
IS
Iceland
Prior art keywords
thienyl
azabicyclo
oct
ene
benzofuryl
Prior art date
Application number
IS5243A
Other languages
English (en)
Other versions
IS5243A (is
Inventor
Peters Dan
M. Olsen Gunnar
Feldbæk Nielsen Simon
Østergaard Nielsen Elsebet
Original Assignee
Neurosearch A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch A/S filed Critical Neurosearch A/S
Publication of IS5243A publication Critical patent/IS5243A/is
Publication of IS2092B publication Critical patent/IS2092B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
IS5243A 1997-05-30 1999-11-10 8-azabísýkló(3,2,1)okt-2-en og oktanafleiður sem kólínergir bindlar á nikótín ach viðtakanum IS2092B (is)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK62797 1997-05-30
DK150297 1997-12-19
DK40898 1998-03-24
DK53498 1998-04-16
PCT/DK1998/000225 WO1998054181A1 (en) 1997-05-30 1998-05-29 8-azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ach receptors

Publications (2)

Publication Number Publication Date
IS5243A IS5243A (is) 1999-11-10
IS2092B true IS2092B (is) 2006-04-12

Family

ID=27439314

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5243A IS2092B (is) 1997-05-30 1999-11-10 8-azabísýkló(3,2,1)okt-2-en og oktanafleiður sem kólínergir bindlar á nikótín ach viðtakanum

Country Status (23)

Country Link
US (2) US6645977B1 (is)
EP (1) EP0984965B1 (is)
JP (1) JP4447663B2 (is)
KR (1) KR100589872B1 (is)
CN (1) CN1157392C (is)
AT (1) ATE267199T1 (is)
AU (1) AU745964B2 (is)
BR (1) BR9809697A (is)
CA (1) CA2289574C (is)
CZ (1) CZ298824B6 (is)
DE (1) DE69823994T2 (is)
DK (1) DK0984965T3 (is)
EE (1) EE04057B1 (is)
HK (1) HK1027353A1 (is)
HU (1) HUP0002713A3 (is)
IL (2) IL132437A0 (is)
IS (1) IS2092B (is)
NO (1) NO325513B1 (is)
NZ (1) NZ500642A (is)
RU (1) RU2186780C2 (is)
SK (1) SK284994B6 (is)
TR (1) TR199902942T2 (is)
WO (1) WO1998054181A1 (is)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001505576A (ja) * 1996-12-02 2001-04-24 ジョージタウン ユニバーシティ トロパン誘導体類及びそれらの合成方法
CA2335336A1 (en) 1998-06-19 1999-12-23 James Edmund Audia Inhibition of serotonin reuptake
US6218383B1 (en) * 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
DE69914935T2 (de) 1998-11-27 2009-10-01 Neurosearch A/S 8-azabicyclo[3.2.1]okt-2-en- und -oktanderivate
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
AU2278700A (en) 1999-01-28 2000-08-18 Neurosearch A/S Novel azabicyclo derivatives and their use
EP1147112B1 (en) * 1999-01-29 2003-10-29 Abbott Laboratories Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
US7265115B2 (en) 1999-01-29 2007-09-04 Abbott Laboratories Diazabicyclic CNS active agents
DE60008866T2 (de) * 1999-05-04 2005-01-27 Neurosearch A/S Heteroaryl diazabicycloalkene, deren herstellung und verwendung
US6890935B2 (en) 1999-11-01 2005-05-10 Targacept, Inc. Pharmaceutical compositions and methods for use
MY137020A (en) * 2000-04-27 2008-12-31 Abbott Lab Diazabicyclic central nervous system active agents
AU6583101A (en) 2000-07-04 2002-01-14 Neurosearch As Aryl and heteroaryl diazabicycloalkanes, their preparation and use
ES2269467T3 (es) * 2000-10-13 2007-04-01 Neurosearch A/S Tratamiento de transtornos afectivos por la accion combinada de un agonista del receptor nicotinico y una sustancia monoaminergenica.
IL160884A0 (en) * 2001-10-02 2004-08-31 Upjohn Co Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
JP2005523288A (ja) 2002-02-19 2005-08-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 疾病治療用の縮合した二環式−ｎ−架橋−複素環式芳香族カルボキサミド
AU2003222738B2 (en) 2002-05-07 2009-09-17 Neurosearch A/S Novel azacyclic ethynyl derivatives
CN1777596A (zh) * 2003-02-28 2006-05-24 先灵公司 作为选择性mch受体拮抗剂用于治疗肥胖及相关病症的联芳基四氢异喹啉哌啶
BRPI0408248A (pt) 2003-03-12 2006-03-01 Pfizer Prod Inc derivados azabicìclicos de piridiloximetila e de benzisoxazol
EP1802258A4 (en) 2004-09-13 2015-09-23 Chrono Therapeutics Inc BIOSYNCHRONE TRANSDERMAL MEDICINES
US20060173037A1 (en) * 2005-01-10 2006-08-03 Nathalie Schlienger Aminophenyl derivatives as selective androgen receptor modulators
DE602006019561D1 (de) 2005-02-16 2011-02-24 Neurosearch As Diazabicyclische arylderivate und ihre verwendung als chinolinergische liganden an nikotin-acetylcholin-rezeptoren
US20090030208A1 (en) * 2005-04-08 2009-01-29 Dan Peters (+) - and (-) -8-Alkyl-3-(Trifluoralkylsulfonyloxy)-8-Azabicyclo(3.2.1.)Oct-2-Ene
FR2889701B1 (fr) * 2005-08-12 2007-10-05 Sanofi Aventis Sa Derives de 5-pyridinyl-1-azabicyclo[3.2.1]octane, leur preparation en therapeutique.
ATE473978T1 (de) 2005-12-06 2010-07-15 Neurosearch As Neue diazabicyclische arylderivate und medizinische verwendung dafür
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
EP1987031A1 (en) 2006-02-10 2008-11-05 NeuroSearch A/S 3-heteroaryl- 3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists
US7700596B2 (en) 2006-02-10 2010-04-20 Neurosearch A/S 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US7687517B2 (en) 2006-02-10 2010-03-30 Neurosearch A/S 3,9-Diazabicyclo [3.3.1] nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
GB2448224B (en) 2007-04-02 2010-09-01 Parkinson S Inst Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent
TWI415850B (zh) * 2007-07-20 2013-11-21 Theravance Inc 製備ｍｕ類鴉片受體拮抗劑之中間物的方法
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US8697722B2 (en) * 2007-11-02 2014-04-15 Sri International Nicotinic acetylcholine receptor modulators
EP2331522B1 (en) * 2008-08-01 2013-09-18 Purdue Pharma LP Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof
EP2367818B1 (en) * 2008-11-18 2018-07-25 Initiator Pharma A/S 8-azabicyclo[3.2.1]oct-2-ene derivatives and their use as mono-amine neurotransmitter re-uptake inhibitors
PL2540297T3 (pl) 2008-11-19 2015-12-31 Forum Pharmaceuticals Inc Leczenie zaburzeń funkcji poznawczych(R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidem i jego farmaceutyczne dopuszczalnymi solami
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
BRPI1014793A2 (pt) * 2009-05-11 2016-04-05 Envivo Pharmaceuticals Inc tratamento de distúrbios de cognição com determinados receptores de ácido alfa-7-nicotínico em combinação com inibidores de acetil-colinesterase
CA2787063C (en) * 2010-01-11 2018-11-27 Astraea Therapeutics, Llc Nicotinic acetylcholine receptor modulators
PL3029039T3 (pl) 2010-05-17 2018-04-30 Forum Pharmaceuticals Inc. Formulacje farmaceutyczne zawierające postacie krystaliczne jednowodnego chlorowodorku (R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidu
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
WO2014011768A1 (en) * 2012-07-10 2014-01-16 Adispell, Inc. Anti-anxiety treatment
US10213586B2 (en) 2015-01-28 2019-02-26 Chrono Therapeutics Inc. Drug delivery methods and systems
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
AU2019279884A1 (en) 2018-05-29 2020-12-10 Morningside Venture Investments Limited Drug delivery methods and systems
KR102272452B1 (ko) 2020-12-11 2021-07-05 (주)예광솔라 스파이럴 파일 공법 및 이에 적용되는 스파이럴 파일
KR200497569Y1 (ko) 2021-02-18 2023-12-21 주식회사 알파인랩 지주 기초용 스크루 파일

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133073A (en) * 1959-12-10 1964-05-12 Sterling Drug Inc 3-aryl-1, 5-iminocycloalkanes and preparation thereof
US3657257A (en) * 1970-08-31 1972-04-18 Robins Co Inc A H 3-aryl-8-carbamoyl nortropanes
CA1244028A (en) 1983-04-14 1988-11-01 Hans Maag Pyrimidine derivatives
GB9019973D0 (en) 1990-09-12 1990-10-24 Wyeth John & Brother Ltd Azabicyclic derivatives
US5045546A (en) 1990-10-26 1991-09-03 Hoechst-Roussel Pharmaceuticals Inc. 8-azabicyclo[3.2.1]octylalkylthiazolidines
FI111367B (fi) 1991-02-04 2003-07-15 Aventis Pharma Inc Menetelmä terapeuttisesti käyttökelpoisten N-(aryylioksialkyyli)heteroaryyli-8-atsabisyklo[3.2.1]oktaanijohdannaisten valmistamiseksi ja menetelmässä käytetyt välituotteet
DK0588917T3 (da) * 1991-05-29 2001-02-12 Abbott Lab Isoxazol- og isothiazolforbindelser, som forstærker kognitiv funktion
US5731317A (en) * 1995-03-10 1998-03-24 Merck & Co., Inc. Bridged piperidines promote release of growth hormone
GB9507203D0 (en) * 1995-04-07 1995-05-31 Smithkline Beecham Plc Novel compounds
AU7083596A (en) * 1995-09-22 1997-04-09 Novo Nordisk A/S Novel substituted azacyclic or azabicyclic compounds
DE69637097T2 (de) * 1995-10-13 2007-09-20 Neurosearch A/S 8-Azabicyclo(3.2.1)Oct-2-en-Derivate, deren Herstellung und Anwendung
GB9706222D0 (en) * 1997-03-26 1997-05-14 Zeneca Ltd Bicyclic amine derivatives
EP0955301A3 (en) * 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
CA2335336A1 (en) * 1998-06-19 1999-12-23 James Edmund Audia Inhibition of serotonin reuptake

Also Published As

Publication number Publication date
CA2289574C (en) 2007-04-24
AU7426198A (en) 1998-12-30
AU745964B2 (en) 2002-04-11
DE69823994T2 (de) 2009-09-24
CN1257499A (zh) 2000-06-21
US6645977B1 (en) 2003-11-11
US6964972B2 (en) 2005-11-15
HK1027353A1 (en) 2001-01-12
EP0984965B1 (en) 2004-05-19
EE04057B1 (et) 2003-06-16
KR20010013154A (ko) 2001-02-26
JP4447663B2 (ja) 2010-04-07
TR199902942T2 (xx) 2000-04-21
EE9900529A (et) 2000-06-15
IL132437A (en) 2006-12-10
JP2002501514A (ja) 2002-01-15
CZ298824B6 (cs) 2008-02-20
HUP0002713A3 (en) 2001-02-28
CA2289574A1 (en) 1998-12-03
SK284994B6 (sk) 2006-04-06
NZ500642A (en) 2001-11-30
BR9809697A (pt) 2000-07-11
CZ414799A3 (cs) 2000-02-16
RU2186780C2 (ru) 2002-08-10
DK0984965T3 (da) 2004-09-27
KR100589872B1 (ko) 2006-06-15
DE69823994D1 (de) 2004-06-24
NO995850L (no) 1999-11-29
CN1157392C (zh) 2004-07-14
WO1998054181A1 (en) 1998-12-03
IL132437A0 (en) 2001-03-19
HUP0002713A2 (hu) 2001-01-29
ATE267199T1 (de) 2004-06-15
NO995850D0 (no) 1999-11-29
IS5243A (is) 1999-11-10
NO325513B1 (no) 2008-05-26
US20040019207A1 (en) 2004-01-29
SK162699A3 (en) 2000-07-11
EP0984965A1 (en) 2000-03-15

Similar Documents

Publication Publication Date Title
IS5243A (is) 8-azabísýkló(3,2,1)okt-2-en og oktanafleiður sem kólínergir bindlar á nikótín ach viðtakanum
US8624040B2 (en) Substituted hydroxamic acids and uses thereof
AU2003248592B2 (en) Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists
TWI357903B (en) Diazabicyclic central nervous system active agents
US7220756B2 (en) N-sulfonylheterocyclopyrrolyl-alkylamine compounds as 5-hydroxytryptamine-6 ligands
RU99128075A (ru) Производные 8-азабицикло(3,2,1)окт-2-ена и-октана в качестве холинергических лигандов на ацх-рецепторах
EP0465254B1 (en) Fused thiophene compounds and uses thereof
US7135484B2 (en) Azabicyclic compounds are central nervous system active agents
US20090264411A1 (en) Fused thiophene derivatives as mek inhibitors
HU211575A9 (en) 2-methyl-thieno-benzodiazepine
WO2005023819A1 (en) Thienopyrroles as antiviral agents
ES2309398T3 (es) Derivados 3,4-dihidro-tieno (2,3-d)pirimidin-4-ona-3-sustituidos, produccion y sus usos.
HUT44791A (en) Process for production of derivatives of 1 h, 3 h-pirrolo /1,2-c/-tiasole
JP2003524633A (ja) キノリンおよびナフチリジンカルボン酸抗菌剤
DK0534343T3 (da) Substituerede pyridinylamino-1H-indoler, 1H-indazoler, 2H-indazoler, benzo[b]thiophener og 1,2-benzoisothiazoler, fremgangs
EP1692141A1 (en) Substituted 3-amino-thieno¬2,3-b| pyridine-2-carboxylic acid amide compounds as ikk inhibitors
WO2010045008A1 (en) AMIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
MXPA05003972A (es) Abridor de canal de k activado por calcio de alta conductancia.
Danieli et al. Indole alkaloids by a chemoenzymatic approach: two convergent routes for the first enantioselective synthesis of (+)-20R-15, 20-dihydrocleavamine
Press Biologically active thiophene derivatives revisited: 1983–1988
MXPA05001726A (es) Compuestos azabiciclicos son agentes activos del sistema nervioso central.
MXPA03011562A (es) Derivados de (pirido/tieno)-(f)-oxazepin-5-ona como moduladores positivos del receptor ampa.